Treating osteoporosis by targeting parathyroid hormone to bone

T. Ponnapakkam, R. Katikaneni, J. Sakon, Robert Stratford Jr., R. C. Gensure

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Osteoporosis is a major public health problem despite widespread use of bisphosphonate therapy. PTH(1-34) is a more effective treatment; but its use has been limited by side effects (hypercalcemia, tumor risk) and inconvenient dosing (daily injection). Long-acting forms of PTH are also effective but cause severe hypercalcemia, presumably from effects in kidney. We hypothesized that targeted delivery of PTH to bone using a collagen binding domain (PTH-CBD) could reduce hypercalcemia. PTH-CBD is cleared from serum within 12 hours after subcutaneous administration. In ovariectomized rats, monthly administration of PTH-CBD increased spinal BMD by 14.2% with no associated hypercalcemia. Such bone-targeted anabolic agents may ultimately allow the superior efficacy of anabolic therapy to be obtained with the dosing convenience of bisphosphonates.

Original languageEnglish (US)
Pages (from-to)204-208
Number of pages5
JournalDrug Discovery Today
Volume19
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Hypercalcemia
Parathyroid Hormone
Osteoporosis
Bone and Bones
Diphosphonates
Anabolic Agents
Collagen
Therapeutics
Public Health
Kidney
Injections
Serum
Neoplasms

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Treating osteoporosis by targeting parathyroid hormone to bone. / Ponnapakkam, T.; Katikaneni, R.; Sakon, J.; Stratford Jr., Robert; Gensure, R. C.

In: Drug Discovery Today, Vol. 19, No. 3, 01.01.2014, p. 204-208.

Research output: Contribution to journalReview article

Ponnapakkam, T. ; Katikaneni, R. ; Sakon, J. ; Stratford Jr., Robert ; Gensure, R. C. / Treating osteoporosis by targeting parathyroid hormone to bone. In: Drug Discovery Today. 2014 ; Vol. 19, No. 3. pp. 204-208.
@article{8600ea1603c5460aa77e80bebeeb40a3,
title = "Treating osteoporosis by targeting parathyroid hormone to bone",
abstract = "Osteoporosis is a major public health problem despite widespread use of bisphosphonate therapy. PTH(1-34) is a more effective treatment; but its use has been limited by side effects (hypercalcemia, tumor risk) and inconvenient dosing (daily injection). Long-acting forms of PTH are also effective but cause severe hypercalcemia, presumably from effects in kidney. We hypothesized that targeted delivery of PTH to bone using a collagen binding domain (PTH-CBD) could reduce hypercalcemia. PTH-CBD is cleared from serum within 12 hours after subcutaneous administration. In ovariectomized rats, monthly administration of PTH-CBD increased spinal BMD by 14.2{\%} with no associated hypercalcemia. Such bone-targeted anabolic agents may ultimately allow the superior efficacy of anabolic therapy to be obtained with the dosing convenience of bisphosphonates.",
author = "T. Ponnapakkam and R. Katikaneni and J. Sakon and {Stratford Jr.}, Robert and Gensure, {R. C.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.drudis.2013.07.015",
language = "English (US)",
volume = "19",
pages = "204--208",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Treating osteoporosis by targeting parathyroid hormone to bone

AU - Ponnapakkam, T.

AU - Katikaneni, R.

AU - Sakon, J.

AU - Stratford Jr., Robert

AU - Gensure, R. C.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Osteoporosis is a major public health problem despite widespread use of bisphosphonate therapy. PTH(1-34) is a more effective treatment; but its use has been limited by side effects (hypercalcemia, tumor risk) and inconvenient dosing (daily injection). Long-acting forms of PTH are also effective but cause severe hypercalcemia, presumably from effects in kidney. We hypothesized that targeted delivery of PTH to bone using a collagen binding domain (PTH-CBD) could reduce hypercalcemia. PTH-CBD is cleared from serum within 12 hours after subcutaneous administration. In ovariectomized rats, monthly administration of PTH-CBD increased spinal BMD by 14.2% with no associated hypercalcemia. Such bone-targeted anabolic agents may ultimately allow the superior efficacy of anabolic therapy to be obtained with the dosing convenience of bisphosphonates.

AB - Osteoporosis is a major public health problem despite widespread use of bisphosphonate therapy. PTH(1-34) is a more effective treatment; but its use has been limited by side effects (hypercalcemia, tumor risk) and inconvenient dosing (daily injection). Long-acting forms of PTH are also effective but cause severe hypercalcemia, presumably from effects in kidney. We hypothesized that targeted delivery of PTH to bone using a collagen binding domain (PTH-CBD) could reduce hypercalcemia. PTH-CBD is cleared from serum within 12 hours after subcutaneous administration. In ovariectomized rats, monthly administration of PTH-CBD increased spinal BMD by 14.2% with no associated hypercalcemia. Such bone-targeted anabolic agents may ultimately allow the superior efficacy of anabolic therapy to be obtained with the dosing convenience of bisphosphonates.

UR - http://www.scopus.com/inward/record.url?scp=84896405316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896405316&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2013.07.015

DO - 10.1016/j.drudis.2013.07.015

M3 - Review article

C2 - 23932952

AN - SCOPUS:84896405316

VL - 19

SP - 204

EP - 208

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

IS - 3

ER -